Expression of KAI1 in Paraffin-Embedded Normal, Hyperplastic and Neoplastic Prostate and Prostate Carcinoma Cell Lines
Document Type
Article
Publication Date
2-1-1998
DOI
http://dx.doi.org/10.1111/j.1440-1827.1998.tb03876.x
Abstract
Expression of KAI1, a tumor metastasis suppressor gene, was studied with different fixatives in frozen and paraffin-embedded sections of human and rat prostate carcinoma cell lines and human prostate lesions by Immunohisto-chemistry. Immunoreactivity of the membrane antigen in cell lines was associated with known expression levels in these lines and the fixative used. Formalin and paraformaldehyde helped maintain the immunoreactivity of cells. In human prostate, frozen sections revealed diffuse reactivity of the antigen in normal and neoplastic tissues while paraffin-embedded tissues usually showed focal reactivity, although more than 50% of cases with normal epithelium and adenocarcinomas were reactive. In some cases, pretreatment with trypsln enhanced immunoreactivity. Benign prostatic hyperplasia (BPH) showed the most intense diffuse immunoreactivity, which suggested enhanced expression. Prostatic intraepithelial neoplasia (PIN) also often expressed high levels of KAI1. Three of five metastases were reactive but two primaries and their metastases were not. Lymphocytes in primary carcinomas and lymphocytes and germinal center cells in lymph nodes were immunoreactive, while adjacent primary or metastatic prostate adenocarcinoma epithelium was not immunoreactive. Although paraffin-embedded human tissues were not optimal for determining levels of expression of KAI1, they did show immunoreactivity that could have prognostic value and showed the specific cytoplasmlc localization of the protein in cells.
Publication Information
Ward, Jerrold M.; Konishi, Noboru; Ohshima, Masato; Lamb, Patricia W.; Jorcyk, Cheryl; and Barrett, J. Carl. (1998). "Expression of KAI1 in Paraffin-Embedded Normal, Hyperplastic and Neoplastic Prostate and Prostate Carcinoma Cell Lines". Pathology International, 48(2), 87-92.